- Home
- SLQT vs RFL Comparison
SLQT vs RFL Comparison
Compare SLQT & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | SLQT | RFL |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Real Estate |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.7M | 133.1M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SLQT | RFL |
|---|---|---|
| Price | $0.53 | $2.61 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $2.88 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 100.9K |
| Earning Date | 05-05-2026 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,618,499,000.00 | $917,000.00 |
| Revenue This Year | $10.97 | N/A |
| Revenue Next Year | $6.14 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 6.02 | ★ 43.96 |
| 52 Week Low | $0.48 | $1.12 |
| 52 Week High | $2.22 | $3.96 |
Technical Indicators
Market Signals| Indicator | SLQT | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 34.68 | 63.32 |
| Support Level | $0.48 | $1.21 |
| Resistance Level | $0.79 | $3.96 |
| Average True Range (ATR) | 0.06 | 0.22 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 13.17 | 71.03 |
Price Performance
Historical ComparisonAbout SLQT SelectQuote Inc.
SelectQuote Inc is a Direct-to-consumer (DTC) distribution platform which facilitates consumers to shop for health, life and auto & home insurance policies online. The company generates its revenues by selling insurance products on behalf of the insurance carrier partners in the form of a commission. It has four reportable segments namely Senior, Healthcare Services, Life, and Auto & Home. It functions through three lines namely, SelectQuote Senior, SelectQuote Life, and SelectQuote Auto & Home.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.